Ингаляционные глюкокортикостероиды в терапии бронхиальной астмы у детей
Ингаляционные глюкокортикостероиды в терапии бронхиальной астмы у детей
Н.А.Геппе, Т.Т.Бераиа. Ингаляционные глюкокортикостероиды в терапии бронхиальной астмы у детей. Consilium Medicum. 2008; 9 (1): 50–53.
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Список литературы
1. Национальная программа «Бронхиальная астма у детей. Стратегии лечения и профилактика». 2006.
2. International Paediatric Asthma Counsensus Group. Asthma: a followup statement from an international paediatric asthma consensus group. Arch Dis Child 1992; 67: 240–8.
3. O'Donohue W. Guidelines for the use of Nebulizere in the home and at comieiliary sites. Chest 1996; 109 (3): 814–20.
4. Bisgaard Н. Palient related factors in nebulized drug delivery to children Eur Respir Rev 1997; 7 (51): 376–7.
5. Shapiro G et al. Efficacy and safety of budesonide inhalation suspension (Pulmicon Repsulf) in young children with inhaled Keroid-dependent peisisien asthma. J Allerg Clin Immunol 1998; 102: 719–96.
6. Kemp J et al. Once-daily budesonide inhalation suspension for the treatment of persistent asthma in infants and young children. Ann Allergy Immunol 1999; 83: 231–9.
7. De Blic J et al. Efficacy of nebulised budesonide in treatment of severe infantile asthma: a double-blind sludy. J Allergy Clin Immunol 1996; 98: 14–20.
8. Pedersen S et al. Dose response relationships to nebulized budesonide in children with asthma. Am J Resp Crit Care Med 1997; 155 (suppl.): A268.
9. Gimfeld A, Llsbros D, Oslincili J et al. Long-lerm study of nebulized budesonide in young children with moderate to severe asthma. Eur Respir J 1994; 7 (Suppl. 18): 278.
2. International Paediatric Asthma Counsensus Group. Asthma: a followup statement from an international paediatric asthma consensus group. Arch Dis Child 1992; 67: 240–8.
3. O'Donohue W. Guidelines for the use of Nebulizere in the home and at comieiliary sites. Chest 1996; 109 (3): 814–20.
4. Bisgaard Н. Palient related factors in nebulized drug delivery to children Eur Respir Rev 1997; 7 (51): 376–7.
5. Shapiro G et al. Efficacy and safety of budesonide inhalation suspension (Pulmicon Repsulf) in young children with inhaled Keroid-dependent peisisien asthma. J Allerg Clin Immunol 1998; 102: 719–96.
6. Kemp J et al. Once-daily budesonide inhalation suspension for the treatment of persistent asthma in infants and young children. Ann Allergy Immunol 1999; 83: 231–9.
7. De Blic J et al. Efficacy of nebulised budesonide in treatment of severe infantile asthma: a double-blind sludy. J Allergy Clin Immunol 1996; 98: 14–20.
8. Pedersen S et al. Dose response relationships to nebulized budesonide in children with asthma. Am J Resp Crit Care Med 1997; 155 (suppl.): A268.
9. Gimfeld A, Llsbros D, Oslincili J et al. Long-lerm study of nebulized budesonide in young children with moderate to severe asthma. Eur Respir J 1994; 7 (Suppl. 18): 278.
Авторы
Н.А.Геппе, Т.Т.Бераиа
ММА им. И.М.Сеченова
ММА им. И.М.Сеченова
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.